Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for ...

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash ... arthritis to Crohn's disease to plaque psoriasis. Now, biosimilar generic versions ...

However, more research is needed to define the cause-and-effect relationship between psoriasis and other diseases. Tumor necrosis factor-a (TNF-a) inhibitors used to treat autoimmune ...

The following medications are indicated for plaque psoriasis, unless otherwise specified. Impoyz 0.025% crm Adults: Apply twice daily; max 50g/week and 2 consecutive weeks’ treatment per course.

Whether you’re looking for a psoriasis treatment with fewer side effects than your current therapy or it affects your daily life, you may want to switch to a biologic. Speaking with your doctor ...

Generally speaking, PASI is used for moderate to severe cases of plaque psoriasis and when you're treated with biologic drugs such as Humira (adalimumab) or Cimzia (certolizumab pegol). The PASI ...

In contrast, Skyrizi saw a 50.8% global increase to $3.205 billion, and Rinvoq rose 45.3% to $1.614 billion. Products such as Humira, Skyrizi, and Rinvoq are used to treat plaque psoriasis, ankylosing ...